Literature DB >> 21268058

Oncogenic role of RUNX3 in head and neck cancer.

Yasusei Kudo1, Takaaki Tsunematsu, Takashi Takata.   

Abstract

Cumulative evidences show that Runt-related transcription factor 3 (RUNX3) has a tumor suppressive role in various cancers. In particular, RUNX3 appears to be an important component of the transforming growth factor-β (TGF-β)-induced tumor suppression pathway. Contrary to reports on this tumor suppressive role of RUNX3, RUNX3 can also function as an oncogene when overexpressed. Recently, we found that RUNX3 overexpression was frequently observed and was well correlated with malignant behaviors in head and neck cancer, which is one of the most common types of human cancer. Moreover, it has been revealed that RUNX3 overexpression promoted cell growth and inhibited apoptosis in head and neck cancer cells. This review introduces the oncogenic role of RUNX3 in certain types of cancer including head and neck cancer.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21268058     DOI: 10.1002/jcb.22967

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  24 in total

1.  RUNX3 expression is associated with sensitivity to pheophorbide a-based photodynamic therapy in keloids.

Authors:  Zhenlong Zheng; Lianhua Zhu; Xianglan Zhang; Lianhua Li; Sook Moon; Mi Ryung Roh; Zhehu Jin
Journal:  Lasers Med Sci       Date:  2014-06-24       Impact factor: 3.161

Review 2.  Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis
Journal:  Drug Resist Updat       Date:  2011-09-14       Impact factor: 18.500

3.  The roles of RUNX3 in cervical cancer cells in vitro.

Authors:  Zhen Li; Pan Fan; Min Deng; Chao Zeng
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

4.  Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions.

Authors:  A Kumar; M Singhal; C Chopra; S Srinivasan; R P Surabhi; R Kanumuri; S Tentu; S Jagadeeshan; S Sundaram; K Ramanathan; R Shankar Pitani; B Muthuswamy; S Abhijit; A S Nair; G Venkatraman; S K Rayala
Journal:  Oncogene       Date:  2016-02-22       Impact factor: 9.867

5.  EZH2 regulates a SETDB1/ΔNp63α axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma.

Authors:  Seamus Balinth; Matthew L Fisher; Yon Hwangbo; Caizhi Wu; Carlos Ballon; Xueqin Sun; Alea A Mills
Journal:  Oncogene       Date:  2022-07-21       Impact factor: 8.756

6.  RUNX3 confers sensitivity to pheophorbide a-photodynamic therapy in human oral squamous cell carcinoma cell lines.

Authors:  Sook Moon; Jung Yoon Bae; Hwa-Kyung Son; Doo Young Lee; Gyeongju Park; Hyun You; Hyojin Ko; Yong-Chul Kim; Jin Kim
Journal:  Lasers Med Sci       Date:  2013-05-23       Impact factor: 3.161

7.  Lineage-specific RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer.

Authors:  B Kurklu; R H Whitehead; E K Ong; T Minamoto; J G Fox; J R Mann; L M Judd; A S Giraud; T R Menheniott
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

8.  Expression of RUNX3 and β-catenin in the carcinogenesis of sporadic colorectal tubular adenoma.

Authors:  Linna Wang; Dan Li; Yang Liu; Yuan Wang; Jinfeng Cui; Airong Cui; Wenxin Wu
Journal:  Tumour Biol       Date:  2014-03-14

9.  Methylation-mediated molecular dysregulation in clinical oral malignancy.

Authors:  Rebecca Towle; Cathie Garnis
Journal:  J Oncol       Date:  2012-05-07       Impact factor: 4.375

10.  Small peptide inhibitor from the sequence of RUNX3 disrupts PAK1-RUNX3 interaction and abrogates its phosphorylation-dependent oncogenic function.

Authors:  Rahul Kanumuri; Aruna Kumar Chelluboyina; Jayashree Biswal; Ravichandran Vignesh; Jaishree Pandian; Akkanapally Venu; B Vaishnavi; D J Leena; Jeyakanthan Jeyaraman; Kumaresan Ganesan; Gopala Krishna Aradhyam; Ganesh Venkatraman; Suresh K Rayala
Journal:  Oncogene       Date:  2021-07-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.